S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula. Primary endpoints Percent change from BL in body weight at Week 12 Change from BL in ...

Cancer cachexia is a multifactorial syndrome characterized by skeletal muscle loss leading to progressive functional impairment. Despite the ubiquity of cachexia in clinical practice, prevention, ...

Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

Tumor cachexia is a serious syndrome affecting many cancer patients, who not only lose significant muscle mass and body weight, but also a considerable amount of quality of life and life expectancy.

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Eating disorders are often thought of as body image disorders with symptoms of food restriction and purging. In most cases, the goal of these behaviors is to prevent weight gain. Not all eating ...

The optimal therapy for anorexia and cachexia is curing the underlying cancer. [23] Unfortunately, this goal is often not attainable with currently available treatments. Thus, an integrated ...